LPA-Targeting Antisense Compounds for Sustained Lp(a) Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for lowering lipoprotein(a) levels are inadequate, particularly for safely and effectively reducing chronic elevations associated with cardiovascular risk, and there is a need for agents that can potently and selectively lower Lp(a) levels with low frequency administration.
Innovation Solution
Development of oligomeric duplexes and modified oligonucleotides, such as antisense agents, that target LPA RNA and Apo(a) protein to reduce their expression and activity, thereby lowering Lp(a) levels in subjects with elevated lipoprotein(a).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current therapeutic strategies (aspirin, Niaspan, Mipomersen, Anacetrapib, Epirotirome, Lomitapide) are used to lower Lp(a) levels, then Lp(a) levels are reduced by 18-43%, but the effectiveness is insufficient for safely reducing chronic elevations and requires frequent administration
Solution Approach 1:
The patent replaces conventional small molecule drugs with antisense oligonucleotide therapy, which operates through a different mechanism (RNA interference) to achieve more potent and sustained Lp(a) reduction. The oligonucleotides bind to LPA mRNA and induce degradation, providing a more reliable and safer approach for chronic elevation compared to traditional lipid-modifying drugs.
2Quantity of substance
If Lp(a) apheresis is used to reduce apo(a) containing Lp(a) particles, then Lp(a) levels are reduced, but it is an invasive procedure with limited availability and requires frequent interventions
Solution Approach 1:
The patent substitutes the mechanical/invasive Lp(a) apheresis procedure with a pharmacological approach using antisense oligonucleotides. This replacement eliminates the need for frequent invasive interventions while providing sustained Lp(a) reduction through oral or intravenous administration, significantly improving ease of operation and patient convenience.
3Quantity of substance
If direct targeting of apo(a) levels is pursued, then Lp(a) levels can be reduced, but no active therapeutics have been approved for commercial use yet
Solution Approach 1:
The patent presents antisense oligonucleotide compounds that are in advanced development stages (clinical trials completed or ongoing) and poised for approval. These compounds have demonstrated safety and efficacy in reducing Lp(a) levels, representing the next generation of therapeutics that will soon transition from experimental to approved treatments, overcoming the current barrier of unapproved status.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligomeric duplexes and modified oligonucleotides effectively reduce Lp(a) levels, ameliorating symptoms of cardiovascular and metabolic diseases by inhibiting LPA expression and Apo(a) protein activity, providing a safe and low-frequency treatment option.
Implementation Method 1
oligomeric duplexes, oligomeric compounds, compositions, and uses therefor, including methods for modulating the amount and/or activity of ApoA expression, LPA RNA
Implementation Method 2
modified oligonucleotides and compounds and compositions comprising them, including, but not limited to, antisense agents, oligomeric agents, oligomeric duplexes
Data Source
AI summary
Provided are oligomeric duplexes, oligomeric compounds and antisense agents, methods, and pharmaceutical compositions for reducing the amount or activity of LPA RNA in a cell or animal, and in certain instances reducing the amount of Lp(a) in a subject. Such oligomeric duplexes, oligomeric compounds and agents, methods, and pharmaceutical compositions are useful to treat or manage inflammatory, cardiovascular and/or metabolic diseases, disorders, or conditions.